In this article, we will take a look at the 11 best quality stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best Quality Stocks to Buy Now.
During these uncertain times, when the Federal Reserve is on a mission to fight inflation by increasing benchmark interest rates, including the best quality stocks in your portfolio can help protect your savings. The Federal Reserve has increased the benchmark interest rates by 75 basis points (bps) the past four times to a range of 3.75% to 4%. Experts anticipate a further 50 bps hike when the Federal Reserve meets in December. Federal Reserve officials anticipate that the benchmark interest rate will peak around the 4.6% level over the next year. Meanwhile, some hawkish members of the Federal Reserve anticipate the interest rate to peak at around the 7% mark. Experts also believe that earnings could fall by 8% next year due to macroeconomic uncertainty.
Amidst the bearish market momentum, it can be difficult to make investments in stocks with strong upside potential. Many analysts think that the quality of a stock can be gauged by its intrinsic value, returns, and earnings quality. However, there is no consensus on one particular basis to gauge quality. Some experts believe that price multiples like price-to-book (P/B) value, price-to-cash flow (P/CF), price-to-earnings before interest, taxes, depreciation, and amortization (P/EBITDA), and price-to-earnings (P/E) ratios are sound measures to determine the quality of a stock. Furthermore, low volatility in the bottom line, high asset turnover and margins, low level of debt, and low-risk profile can also be considered indicators of high-quality stocks. In line with these metrics, companies like Microsoft Corporation (NASDAQ:MSFT), Apple Inc. (NASDAQ:AAPL), and NVIDIA Corporation (NASDAQ:NVDA) are considered some of the best quality stocks in the market currently.
11 Best Quality Stocks to Buy Now
Photo by Ruben Sukatendel on Unsplash Our Methodology
We have shortlisted the 11 best quality stocks based on their business fundamentals and earnings quality. These companies have shown strong growth in earnings on a YoY basis and are expected to help investors yield decent returns in the long term. Furthermore, these companies are blue-chip stocks with sound business models and industry-leading positions. Most of these stocks also offer attractive annual dividend yields as of December 5. The stocks have been ranked using Insider Monkey's database of 920 hedge funds as of Q3 2022.
Lockheed Martin Corporation (NYSE:LMT) is a Maryland-based aerospace, arms, defense, information security, and technology corporation with a global presence.
The maker of the F-35 fighter has emerged as the biggest contract recipient with the US Department of Defense. Lockheed Martin Corporation (NYSE:LMT) received $39.2 billion worth of contracts from the Pentagon over the last year. Following the better-than-expected Q3 2022 results and an expanded share buyback plan, Peter J. Arment at Baird upgraded Lockheed Martin Corporation (NYSE:LMT) stock from a Neutral to an Outperform rating while maintaining a target price of $513 on October 19.
The analyst believes that the company’s ability to generate strong cash flows is still in place, and the strong buyback plan in a volatile market limits the downside potential of Lockheed Martin Corporation (NYSE:LMT). Furthermore, Lockheed Martin Corporation (NYSE:LMT) is expected to be a beneficiary of a ramped-up global defense expenditure at a time when tensions between global powers are high. The stock offers an annual forward dividend yield of 2.48% as of December 5.
Vltava Fund discussed its outlook on Lockheed Martin Corporation (NYSE:LMT) in its Q3 2022 investor letter. Here’s what the firm said:
“LMT is one of the world’s largest aerospace and defence companies. The war in Ukraine has reminded investors and the wider public just how important these companies are. The aerospace and defence industry in the USA is an established oligopoly. This means that a few large firms play a dominant role. While collectively they comprise an oligopoly, individually they often have monopoly positions in particular narrower segments. Their main counterparty is the US government, a key customer in what is known as a monopsonist position. This is a rather unusual situation, but one that is very advantageous for companies such as LMT.
The Coca-Cola Company (NYSE:KO) is a Georgia-based beverage company with a global footprint. The company claims that over 1.9 billion servings of its beverages are consumed across more than 200 countries every day.
In a research note issued on October 26, Peter Grom at UBS maintained a Buy rating on The Coca-Cola Company (NYSE:KO) stock and increased the price target from $63 to $68. The analyst termed the Q3 2022 results as strong and the increase in financial guidance as impressive. This was due to organic growth that was able to offset the adverse impact of currency fluctuation. The analyst believes that The Coca-Cola Company (NYSE:KO) can trade at a premium against its peers due to the possibility of strong revenue growth in the upcoming quarters. This makes the risk and reward profile of the stock favorable for potential investors. Experts believe that The Coca-Cola Company (NYSE:KO) has a price leadership position in the market and an advanced top-line growth management strategy that is expected to provide impetus to the top line. The Coca-Cola Company's (NYSE:KO) annual dividend yield stands at 2.74% as of December 5.
“The Coca-Cola Company (NYSE:KO), the global beverage business, was a leading contributor for the period. Coca-Cola continues to benefit from the refranchising of its bottling operations and realignment of incentives, catalysts we previously identified. These initiatives are demonstrating their strength in an inflationary and supply-chain-challenged environment. Additionally, the company has focused on evolving its customer engagement practices by leveraging digital and social medias for targeted campaigns, such as the design and launch of Coke Byte in the metaverse. Lastly, Coca-Cola has furthered its transformation into a total beverage company, as it debuted its new Jack Daniel’s Tennessee Whiskey and Coca-Cola ready-to-drink premixed cocktail. Although uncertainties surrounding cost pressures, lockdowns and geopolitical conflicts remain, we believe Coca-Cola is uniquely positioned to successfully continue its transition toward a total beverage business.”
Costco Wholesale Corporation (NASDAQ:COST) is the third biggest retailer in the world. The Issaquah, Washington-based company operates as a membership-only big box retailer with large warehouses.
Analysts at Bank of America added Costco Wholesale Corporation (NASDAQ:COST) stock to the 'US 1 List' on November 22. The 'US 1 List' comprises the best investment ideas across all the sectors that are covered by the analysts at Bank of America. Experts believe that retailers like Costco Wholesale Corporation (NASDAQ:COST) will perform strongly through their low-priced private label brands as the consumer is trading down and buying fewer items. The holiday season is expected to provide a boost to the company due to higher consumer spending. Given the raging inflation, people will be looking for value, and Costco Wholesale Corporation (NASDAQ:COST) falls under that category. Furthermore, the company’s membership program is also going strong as the annual renewal rate sits around the 90% mark. The stock's annual payout stands at $3.60, translating into a dividend yield of 0.68% as of December 5.
Cooper Investors shared its outlook on Costco Wholesale Corporation (NASDAQ:COST) in its Q3 2022 investor letter. Here’s what the firm said:
“The US economy continues to run hot – the labour market is extremely tight and a number of executives we spoke to described their challenges in retaining staff and preventing competitors from poaching talent. Industrial companies in particular continue to see record backlogs, with the easing of logistics and supply chain constraints only just starting to have an impact on deliveries and lead times.
NIKE, Inc. (NYSE:NKE) is a Beaverton, Oregon-based company known for its footwear, apparel, accessories, and equipment with a sports-based theme. The company is at the eighth position on our list of the 11 best quality stocks to buy now.
On November 15, NIKE, Inc. (NYSE:NKE) increased its quarterly dividend by 11% to 34 cents per share. The company is on track to become a member of the Dividend Aristocrat list as it has been raising its annual dividend for the past 15 consecutive years. On October 13, Rick Patel at Raymond James initiated coverage on NIKE, Inc. (NYSE:NKE) with an Outperform rating and a target price of $99. Although the stock is in the red YTD due to macroeconomic headwinds and industry-specific challenges, the analyst has a long-term bullish take on NIKE, Inc. (NYSE:NKE). Experts believe that the company will continue to grow due to its globally renowned brand, out-of-the-box products, and high growth in emerging markets.
Leaven Partners discussed its outlook on NIKE, Inc. (NYSE:NKE) in its Q3 2022 investor letter. Here’s what the firm said:
“In our last quarterly letter, I briefly mentioned that the consensus estimates for corporate profits appeared to be a bit too sanguine. I referenced a Reuters article that reported, as of June 17, Wall Street expected S&P 500 earnings to grow by 9.6% in 2022, which was up from 8.8% in April and from 8.4% in January. That tune began to change at the end of July and accelerated in August and September, as major players, such as NIKE (NYSE:NKE), has recently issued profit warnings and/or have withdrawn guidance. In response, Wall Street has altered its outlook: lowering third-quarter profit growth to 4.6%[2] from 7.2% in early August and slashing full-year profit growth to 4.5%.”
NIKE, Inc. (NYSE:NKE) was held by 70 hedge funds at the end of Q3 2022.
Eli Lilly and Company (NYSE:LLY) is an Indianapolis, Indiana-based pharmaceutical company founded in 1876. The products of the company are sold in over 120 countries and manufactured in seven countries.
Kerry Holford at Berenberg increased the price target on Eli Lilly and Company (NYSE:LLY) from $345 to $375 and maintained a Buy rating on the stock in a research note issued to investors on November 22. The analyst observed that the underlying performance of the large-cap pharma entity is stellar. Furthermore, the early reports regarding the launch of Mounjaro are positive. The injectable for adults suffering from type 2 diabetes has also received a label expansion as a medication against obesity and is expected to roll out by the end of 2023. Experts believe that Eli Lilly and Company (NYSE:LLY) is heading towards a favorable setup with the possibility of donanemab providing more upside in treating Alzheimer's. As of December 5, Eli Lilly and Company (NYSE:LLY) has an annual forward dividend yield of 1.05%.
Eli Lilly and Company (NYSE:LLY) was discussed in the Q3 2022 investor letter of ClearBridge Investments. Here’s what the firm said:
“In the U.S., we initiated a position in pharmaceutical maker Eli Lilly (NYSE:LLY) as it brings out new drug candidates for diabetes and Alzheimer’s disease. New drugs impact diabetes but have also demonstrated significant weight loss for patients who are overweight and have other co-morbidity issues as a result. Lilly is one of the two key players in diabetes care and we believe the potential market opportunity is much higher than the consensus forecasts as we are seeing evidence of accelerating adoption.”
Johnson & Johnson (NYSE:JNJ) is a New Brunswick, New Jersey-based pharmaceutical, medical devices, and consumer goods company. The company is focused on spinning off its consumer goods business as a separate publicly listed entity to focus more on the core pharmaceutical and medical devices segment.
To provide impetus to the core business, Johnson & Johnson (NYSE:JNJ) has announced the acquisition of Abiomed, Inc. (NASDAQ:ABMD) for $16.6 billion. The takeover of the Danvers, Massachusetts-based heart, lung, and kidney support device maker reflects the next growth frontier for the company following the success of the COVID-19 vaccine. Experts believe that the spin-off of the consumer division will provide value to the investors. Moreover, Johnson & Johnson (NYSE:JNJ) is targeting to achieve annual revenue of $60 billion through the pharmaceutical and medical devices business by 2025. Experts believe that large-cap pharma stocks provide defensive cover during uncertain times, making Johnson & Johnson (NYSE:JNJ) one of the best quality stocks to buy now. Johnson & Johnson (NYSE:JNJ) is a Dividend King and offers a forward dividend yield of 2.58% as of December 5.
Here's what Mayar Capital said about Johnson & Johnson (NYSE:JNJ) in its Q2 2022 investor letter:
“J&J is currently our largest position and a long-standing holding. The majority of the group’s sales comes from its collection of pharmaceutical franchises, but a large majority (~45%) comes from its collection of medical device businesses and its consumer brands.
In addition to Johnson & Johnson (NYSE:JNJ), companies like Microsoft Corporation (NASDAQ:MSFT), Apple Inc. (NASDAQ:AAPL), and NVIDIA Corporation (NASDAQ:NVDA) are also among the best quality stocks to buy now.
